Crystalline forms of (2R,5S,13aR)-8-hydroxy-7,9-dioxo-N-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido [1',2':4,5] pyrazino [2,1-b] [1,3] oxazepine-10-carboxamide
Carra, Ernest A.,Chen, Irene,Keaton, Katie Ann,Zia, Vahid
申请号：
AU2018203737
公开号：
AU2018203737A1
申请日:
2018.05.28
申请国别(地区):
AU
年份:
2018
代理人:
摘要：
#$%^&*AU2018203737A120180621.pdf#####C: Interwovn NRPortbl DCC RBR 17063756 Idocx-28 05/2018 ABSTRACT The present invention relates to crystalline forms and co-crystals of (2R,5S,13aR)-8hydroxy-7,9-dioxo-N-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,55 methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide, the pharmaceutical formulations, and the therapeutic uses thereof. The present invention also relates to novel crystalline forms of sodium (2R,5 S,13 aR)-7,9-dioxo- 1 0-((2,4,6-trifluorobenzyl)carbamoyl)2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepin-8olate Form I.WO 2015/196137 PCT/US2015/036784 1/16 . 1200 0 1000 800 600 400 200 0 5 10 15 20 25 30 35 2Theta (0) Figure 1
